Stockscreener 앱 받기
1.304
1.09%
0.014
전일 마감가:
$1.29
열려 있는:
$1.29
하루 거래량:
7,970
Relative Volume:
0.18
시가총액:
$4.12M
수익:
$129.20K
순이익/손실:
$-7.44M
주가수익비율:
-0.1165
EPS:
-11.19
순현금흐름:
$-8.62M
1주 성능:
-1.95%
1개월 성능:
+3.49%
6개월 성능:
-57.11%
1년 성능:
-91.14%
1일 변동 폭
$1.29
$1.3195
1주일 범위
$1.21
$1.3498
52주 변동 폭
$1.10
$16.00
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
명칭
Sonnet Biotherapeutics Holdings Inc
전화
609-375-2227
주소
100 OVERLOOK CENTER, PRINCETON, NJ
SONN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.30 | 4.08M | 129.20K | -7.44M | -8.62M | -11.19 |
|
ONC
Beigene Ltd Adr
|
231.35 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.38 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3045 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.77 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.80 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Sonnet Biotherapeutics Holdings Inc 주식(SONN)의 최신 뉴스
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Tuesday - Defense World
Sonnet Chief Medical Officer, Richard Kenney, M.D., to - GlobeNewswire
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - The Globe and Mail
Chanticleer Holdings Little Big Burger Partner and Brand Ambassador Denny Hamlin Wins the Daytona 500 - marketscreener.com
Sonnet Releases Virtual Investor "What This Means" Segment | SONN Stock News - GuruFocus
Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment - Nasdaq
Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire
Biotech Leader Dr. Pankaj Mohan Honored on NASDAQ After Tragic Crash - newsindiatimes.com
Sonnet BioTherapeutics (NASDAQ:SONN) Receives Buy Rating from Chardan Capital - Defense World
SONN stock touches 52-week low at $1.18 amid market challenges - Investing.com India
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance
Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener
Sonnet BioTherapeutics advances in cancer trial By Investing.com - Investing.com South Africa
Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times
Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada
Sonnet Announces Release of Corporate Update Video - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com
Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks
Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts
Pilot killed in N.J. plane crash was biotech company founder, CEO - NJ.com
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz
Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - marketscreener.com
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World
Sonnet BioTherapeutics secures new IL-18 patent - Investing.com
Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks
Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - Yahoo
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq
Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan
Sonnet Biotherapeutics Holdings Inc (SONN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.93%
자본화:
|
볼륨(24시간):